Sitagliptin Phosphate Monohydrate

磷酸西格列汀一水合物

Report date: 2023/12/26 13:48:23
NMEFirst In Class

Base Information

Drug NameSitagliptin Phosphate Monohydrate
Drug Alias Name磷酸西他列汀sitagliptinum磷酸西他列汀单水合物sitagliptinesitagliptina +[20
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationGraft vs Host Disease +[29
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2006/10/16
Country/TerritoryCanadaUnited StatesItaly +[12
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)InflammationGraft vs Host Disease +[28

Other Information

ATC CodeA10BH01